FDA News - Approves new MS treatment
FDA approves new multiple sclerosis treatment Aubagio – making it the second oral therapy that will be available on the U.S. market. Most MS treatments are injectables.
The U.S. Food and Drug Administration approved Aubagio (teriflunomide) yesterday, a once-a-day tablet for the treatment of adults with relapsing forms of multiple sclerosis (MS).
“In a clinical trial, the relapse rate for patients using Aubagio was about 30 percent lower than the rate for those taking a placebo,” said Russell Katz, M.D., director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “Multiple sclerosis can impair movement, sensation, and thinking, so it is important to have a variety of treatment options available to patients.”
MS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body. It is among the most common causes of neurological disability in young adults and occurs at least twice as frequently in women as in men. For most people with MS, episodes of worsening function (relapses) are initially followed by recovery periods (remissions).
For information and consumer inquiries: 888-INFO-FDA
Press + Media
- Print Press Coverage
- TV Press Coverage
- Online Press Coverage
- Foundation Videos
- Foundation Blog
- Press Materials
Topics of Interest
Posted: Aug 20, 2015A recently published study in the journal Neurology entitled “lower physical activity is associated with higher disease ...
Posted: May 12, 2014Please join us for an opportunity to hear from our ...
Posted: Apr 07, 2014Please join us on May 2, 2014 at the Hyatt ...
Posted: Sep 24, 2013Taking place at the Hyatt Regency Century City on December ...